Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.

Szczegóły
Abstrakt

Tytuł:: Human/eukaryotic ribosomal protein L14 (RPL14/eL14) overexpression represses proliferation, migration, invasion and EMT process in nasopharyngeal carcinoma.
Autorzy:: Zhang Z; Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Zhang Y; Department of Ultrasonic Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Qiu Y; Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Mo W; Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Yang Z; Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China.
Źródło:: Bioengineered [Bioengineered] 2021 Dec; Vol. 12 (1), pp. 2175-2186.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin : Landes Bioscience
MeSH Terms:: Nasopharyngeal Carcinoma/*genetics
Nasopharyngeal Neoplasms/*genetics
Ribosomal Proteins/*genetics
Adult ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cadherins/genetics ; Cadherins/metabolism ; Cell Line, Tumor ; Epithelial-Mesenchymal Transition/genetics ; Female ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/metabolism ; Nasopharyngeal Carcinoma/pathology ; Nasopharyngeal Neoplasms/metabolism ; Nasopharyngeal Neoplasms/pathology ; Nasopharynx/metabolism ; Nasopharynx/pathology ; Ribosomal Proteins/metabolism ; Vimentin/genetics ; Vimentin/metabolism
References:: Gene. 2006 Jan 17;366(1):161-8. (PMID: 16316724)
PLoS One. 2012;7(7):e41055. (PMID: 22815911)
Onco Targets Ther. 2019 Dec 02;12:10535-10545. (PMID: 31849480)
Biosci Rep. 2021 Jan 29;41(1):. (PMID: 33305312)
Lancet Oncol. 2018 Mar;19(3):382-393. (PMID: 29428165)
Medicine (Baltimore). 2020 Aug 7;99(32):e21505. (PMID: 32769887)
CA Cancer J Clin. 2015 Mar;65(2):87-108. (PMID: 25651787)
Toxicol Lett. 2008 Jun 10;179(1):1-5. (PMID: 18485627)
PLoS One. 2014 Oct 06;9(10):e108743. (PMID: 25285958)
PLoS One. 2016 Nov 3;11(11):e0166021. (PMID: 27812193)
Biomed Res Int. 2020 Jun 22;2020:4234632. (PMID: 32685483)
Cancer Med. 2015 Jul;4(7):1079-90. (PMID: 25924914)
Front Oncol. 2019 Oct 11;9:1044. (PMID: 31681582)
Bioengineered. 2021 Dec;12(1):96-107. (PMID: 33345740)
J Histochem Cytochem. 2003 May;51(5):567-74. (PMID: 12704204)
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4959-70. (PMID: 25197367)
Biomed Res Int. 2020 Aug 7;2020:1970936. (PMID: 33134371)
Clin Epigenetics. 2019 Dec 30;11(1):199. (PMID: 31888761)
Front Oncol. 2018 Oct 26;8:483. (PMID: 30416986)
Onco Targets Ther. 2021 Jan 19;14:551-564. (PMID: 33505161)
Toxicol Lett. 2011 Mar 25;201(3):205-12. (PMID: 21195149)
BMC Med Imaging. 2020 Sep 1;20(1):104. (PMID: 32873238)
Semin Cancer Biol. 2012 Apr;22(2):79-86. (PMID: 22245473)
Crit Rev Oncol Hematol. 1999 Jun;31(1):55-69. (PMID: 10532190)
Mol Cancer Res. 2007 Feb;5(2):171-81. (PMID: 17314274)
Oncotarget. 2017 Feb 14;8(7):12052-12066. (PMID: 28076843)
Mol Med Rep. 2020 Sep;22(3):2478-2486. (PMID: 32705264)
Int J Biol Sci. 2018 Apr 5;14(5):549-556. (PMID: 29805306)
J Cancer. 2017 Oct 19;8(18):3876-3886. (PMID: 29151976)
PLoS One. 2012;7(5):e37765. (PMID: 22662215)
Biochem Biophys Res Commun. 2019 May 21;513(1):56-63. (PMID: 30935691)
Cell J. 2016 Jul-Sep;18(2):159-64. (PMID: 27540520)
J Cell Physiol. 2017 Dec;232(12):3261-3272. (PMID: 28079253)
Pathol Oncol Res. 2020 Jul;26(3):1893-1901. (PMID: 31832991)
Bioengineered. 2021 Dec;12(1):414-425. (PMID: 33467964)
Med Oncol. 2016 Feb;33(2):11. (PMID: 26732474)
Biomolecules. 2019 May 24;9(5):. (PMID: 31137733)
Mol Med Rep. 2019 Mar;19(3):2065-2076. (PMID: 30664178)
Biochem Pharmacol. 2012 Nov 15;84(10):1268-76. (PMID: 22842489)
Mutat Res. 1998 Nov;406(1):9-23. (PMID: 9920051)
J Cancer. 2020 Oct 21;11(24):7291-7301. (PMID: 33193893)
Lancet Oncol. 2016 Nov;17(11):1509-1520. (PMID: 27686945)
J Clin Oncol. 2015 Oct 10;33(29):3356-64. (PMID: 26351355)
South Asian J Cancer. 2018 Jul-Sep;7(3):183-187. (PMID: 30112335)
Nucleic Acids Res. 2020 Jul 27;48(13):7079-7098. (PMID: 32525984)
Contributed Indexing:: Keywords: EMT process; Nasopharyngeal carcinoma; RPL14(eL14); progression; ribosomal protein
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Cadherins)
0 (Ribosomal Proteins)
0 (Vimentin)
0 (ribosomal protein L14)
Entry Date(s):: Date Created: 20210531 Date Completed: 20211126 Latest Revision: 20220204
Update Code:: 20240105
PubMed Central ID:: PMC8806664
DOI:: 10.1080/21655979.2021.1932225
PMID:: 34057029
: Czasopismo naukowe

Full Text Finder

Although human/eukaryotic ribosomal protein L14 (RPL14/eL14) is known to be associated with a variety of cancers, its role in nasopharyngeal carcinoma (NPC) remains unclear. The aim of this study was to explore the impact of RPL14(eL14) in NPC. The results of quantitative real-time polymerase chain reaction (qRT-PCR), western blot, and immunohistochemical staining revealed that the expression of RPL14(eL14) significantly reduced in NPC tissues and cells. Furthermore, the protein expression of RPL14(eL14) was linked to NPC-related clinical pathological features, including the T and N classification of Tumor Node Metastasis (TNM) staging (all p < 0.05). Cell counting kit-8 (CCK-8) assay and colony formation assay revealed that RPL14(eL14) overexpression repressed NPC cell proliferation. In cell cycle assay, RPL14(eL14) overexpression significantly blocked NPC cells in S phase. Overexpression of RPL14(eL14) repressed cell migration and invasion in NPC as shown by transwell assay and cell scratch healing assay. In addition, RPL14(eL14) was closely correlated with the expression of epithelial-mesenchymal transition (EMT) biomarkers, including E-cadherin, N-cadherin, and vimentin as detected by western blot. In conclusion, our results revealed that RPL14(eL14) may be considered as an antioncogene in NPC, which greatly suppresses cancer progression.

Informacja